Centene Corporation Q3 2026 Earnings: Revenue Hits $50.65 Billion, Beats Estimates

Quick Verdict

Centene Corporation Q3 2026 Earnings results were released, showing Centene reported third-quarter revenue of $50.65 billion and adjusted EPS of $0.58, beating analyst expectations, while GAAP EPS showed a $0.14 loss. Management raised its full-year adjusted earnings outlook above $5.20 per share. Shares nevertheless slipped about 2% in premarket trading, according to reporting published on October 27.

About Centene Corporation

Centene Corporation (NYSE: CNC) provides government-sponsored and commercial health insurance, focusing on people who are uninsured or underinsured. Founded in 1984 as a nonprofit Medicaid plan in Milwaukee, the company adopted the Centene name and moved its headquarters to St. Louis, Missouri, in 1997. Its major businesses include Medicaid managed care, Medicare Advantage, Medicare prescription drug plans, and individual coverage sold through the Health Insurance Marketplace.

As of September 30, 2026, Centene served approximately 25.7 million at-risk members and employed 53,900 people. Medicaid remained its largest premium-and-service revenue contributor, while Medicare growth helped offset a substantial contraction in Commercial revenue. Its results depend on the relationship between insurance premiums, medical spending, membership, and administrative costs. The quarter illustrates those competing pressures: adjusted earnings improved, but restructuring expenses contributed to a GAAP loss. A contemporaneous market capitalization and current P/E ratio were not verified in the sources reviewed and are therefore omitted rather than estimated.

Top Financial Highlights

1. Total revenue: $50.647 billion, up 1.9% from $49.690 billion a year earlier.
2. Premium and service revenue: $45.105 billion, up 0.5%; this excludes premium-tax revenue included in consolidated total revenue.
3. GAAP net loss attributable to Centene: $71 million, compared with a $6.631 billion loss in Q3 2025.
4. GAAP diluted EPS: A loss of $0.14, versus a loss of $13.50 a year earlier.
5. Adjusted diluted EPS: $0.58, up 16% from $0.50; adjusted net earnings increased to $290 million from $245 million.
6. Medical-cost performance: The health benefits ratio, or HBR, was 92.7%, unchanged year over year. Conventional gross margin was not separately reported; HBR measures medical costs divided by premium revenue and is not an equivalent gross-margin measure.
7. Operating cash flow: A quarterly outflow of $3.669 billion, attributed primarily to payment timing. Nine-month operating cash flow remained positive at $4.287 billion.
8. Medicaid premium and service revenue: $24.039 billion, up approximately 4%.
9. Medicare premium and service revenue: $11.263 billion, up approximately 20%.
10. Commercial premium and service revenue: $8.700 billion, down approximately 21%.
11. Administrative efficiency: Adjusted SG&A expense ratio fell to 6.5% from 7.0%, although the GAAP ratio increased to 7.2% from 7.0%.
12. Cash on hand: Cash and cash equivalents totaled $20.700 billion. Separately, cash available for general corporate use was $175 million; these figures should not be treated as interchangeable.
13. Broader liquidity and debt: Cash, investments, and restricted deposits totaled $39.850 billion, while quarter-end total debt was approximately $15.5 billion.
14. Guidance: Full-year adjusted diluted EPS is expected to exceed $5.20, a $0.40 increase in the guidance floor. Total revenue guidance is $196.5 billion–$200.5 billion. Standalone fourth-quarter guidance was not provided in the release.

Beat or Miss?

Centene delivered a beat on both adjusted EPS and total revenue. Consensus figures differ across providers, so the comparison below uses the estimates reported by Investing.com through Yahoo Finance consistently rather than mixing datasets.

The revenue distinction matters: consolidated revenue includes $5.542 billion of premium-tax revenue, while the business-line figures above cover premium and service revenue only. Comparing the latter with a total-revenue consensus would produce a misleading conclusion.

What Leadership Is Saying

“Solid underlying fundamentals within our core businesses have powered a faster recovery to our earnings trajectory than previously anticipated.” — Sarah M. London, Chief Executive Officer.

London connected that recovery to improved margins and management’s focus on finishing 2026 strongly while building momentum into 2027.

“The Company is updating its 2026 GAAP diluted EPS guidance floor to greater than $3.46 and its 2026 adjusted diluted EPS guidance floor to greater than $5.20.”
— Centene’s earnings release; not a quotation attributed to the CFO.

The release contains no direct CFO quotation. Earnings-call coverage attributes to CFO Drew Asher the explanation that prescription drug plans accounted for most of Medicare’s outperformance, alongside expected Marketplace pretax-margin improvement from negative 1% in 2025 to approximately 5% in 2026. That coverage paraphrases his remarks, so it is not presented here as a verbatim quotation.

Historical Performance

The dramatic GAAP improvement requires context. Q3 2025 included a $6.723 billion goodwill impairment, whereas Q3 2026 included significant enterprise-optimization charges. The absence of the prior-year impairment explains much of the reduction in reported operating expenses and net losses; the 16% adjusted-EPS increase provides a less distorted view of earnings progress, although it remains a non-GAAP measure.

Competitor comparison: Elevance Health

Elevance Health provides a relevant peer comparison through its Health Benefits and Carelon businesses. It released its Q3 2026 results on October 21, before Centene’s announcement. The retrieved release text did not include complete consolidated financial statement tables, so unavailable net-income figures are explicitly marked rather than inferred from EPS.

Elevance figures are rounded; its published 0.7% revenue growth uses underlying figures rather than the rounded amounts displayed here. The expense-ratio comparison uses a disclosed alternative to operating-expense dollars.

Both companies reported improved medical-cost performance and raised annual earnings guidance. However, Elevance’s operating revenue and expense definitions differ from Centene’s consolidated total-revenue and SG&A measures, so the dollar totals and ratios are not directly interchangeable.

How the Market Reacted?

Centene shares slipped approximately 2% in premarket trading on October 27 despite the earnings beat and higher full-year outlook. That is a reported premarket move, not an after-hours reaction or a verified closing-price change. Subsequent October 28 coverage reported that BofA raised its price target to $82 from $80 while maintaining a Buy rating, citing progress on Medicaid rates and margins.

Together, these reports show a negative immediate stock reaction alongside a constructive response from at least one analyst; they do not establish a single cause for the share-price decline.